Acceptability of Hepatitis C screening and treatment during pregnancy in pregnant women in Egypt, Pakistan and Ukraine
medrxiv(2021)
Abstract
The risk of vertical transmission of hepatitis C virus (HCV) is ≈6%, and there is growing evidence that maternal HCV adversely affects pregnancy and infant outcomes. However, antenatal HCV screening is not routinely provided in most settings, and direct acting antivirals (DAA) are not approved for pregnant/ breastfeeding women. We conducted a cross-sectional survey of pregnant/post-partum women in Egypt, Pakistan and Ukraine to assess the acceptability of universal antenatal HCV screening and DAA treatment in the scenario of DAAs being approved for use in pregnancy. Among 630 women (n=210 per country), 73% were pregnant and 27% postpartum, 27% ever HCV antibody or PCR positive. Overall, 93% of women supported HCV screening and 88% would take DAAs in pregnancy (92%, 98% and 73% in Egypt, Pakistan and Ukraine, respectively), mostly to prevent vertical transmission/adverse pregnancy outcomes. Clinical trials to evaluate the safety and efficacy of DAAs in pregnancy are urgently needed.
### Competing Interest Statement
MHE-S received an educational grant to attend EASL 2019 (Gilead Sciences) and minor honorarium for participating in a podcast on career development and achievements in viral hepatitis (Gilead Sciences).
### Funding Statement
This survey was conducted as part of the HCVAVERT study, funded by the UK Medical Research Council (ref MR/R019746/1).
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UCL Research Ethics Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data sharing requests may be made in writing to UCL
* HCV
: Hepatitis C virus
DAAs
: Direct acting antivirals
PCR
: Polymerase chain reaction
WHO
: World Health Organization
RNA
: Ribonucleic acid
LMIC
: Low and middle-income countries
HIV
: Human immunodeficiency virus
MoreTranslated text
Key words
pregnant women,pregnancy,screening
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined